Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction (FNB for ACLR)

Mahidol University

Status and phase: Completed; Phase 4

Conditions: Analgesia After ACL Reconstruction

Treatments: Drug: 0.25% Bupivacaine; Drug: 0.5% Bupivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT01593566

Mahidol University

Details and patient eligibility

About

Femoral nerve block using 0.25% bupivacaine or 0.5% bupivacaine provides a longer time for analgesia after Anterior Cruciate Ligament (ACL) reconstruction.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients scheduled for ACL reconstruction
• ASA physical status I-II
• Body weight > or = 50 kg.

Exclusion criteria

• Patients with redo ACL reconstruction
• Contraindication to neuraxial block
• allergy to local anesthetics, sulfa, NSAIDs, morphine, paracetamol
• Patients with communication problem

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups

0.25% bupivacaine

Active Comparator group

Description:

femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine

Treatment:

Drug: 0.25% Bupivacaine

0.5% bupivacaine

Active Comparator group

Description:

femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine

Treatment:

Drug: 0.5% Bupivacaine